Le Lézard
Classified in: Health, Science and technology
Subjects: BFA, FVT, SHM

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City


SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include updates on several ongoing initiatives in the Acute Care franchise to expand reach and adoption. 

The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the Company website at Investor Resources - Heron Therapeutics (herontx.com) to register for the webcast and for additional information on the event.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

 

SOURCE Heron Therapeutics, Inc.


These press releases may also interest you

at 17:55
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The...

at 17:54
Meddux appoints Ben Trombold as new VP of Sales & Marketing
Meddux is thrilled to announce the appointment of Ben Trombold as the new Vice President of Sales & Marketing. With over 14 years of dedicated experience in the sales and marketing sector, Trombold brings a wealth of expertise and a proven track...

at 17:31
Malignant Ascites Market to Observe Growth at a CAGR of 1.2% by 2034 | DelveInsight
DelveInsight's Malignant Ascites Market Insights report includes a comprehensive understanding of current treatment practices, malignant ascites emerging...

at 17:26
Amped Fitness® Debuts All-New Luxury Signature Location in West Palm Beach, FL
Amped Fitness® has recently unveiled their highly anticipated luxury fitness oasis in the heart of West Palm Beach, FL. With fitness centers already booming throughout the South Florida area, Amped Fitness® is thrilled to announce their first ever...

at 17:18
SHATTERPROOF AND ANTHEM BLUE CROSS FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER IN CALIFORNIA
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

at 17:15
AANA Presents U.S. Representative Jen Kiggans With National Health Leadership Award
(AANA) ? The American Association of Nurse Anesthesiology (AANA) recognized U.S. Representative Jen Kiggans (R-VA) as the winner of its National Health Leadership Award for 2024 at its Mid-Year Assembly, April 20-24, in Washington, DC....

More news about Health...


News published on and distributed by: